Effect of Partial Dietary Replacement From Animal to Plant-Based Protein for Type 2 Diabetes Management

Exclusion Criteria

• •Type 1 diabetes mellitus;
• •Retinopathy with vision deficit that limits the activities proposed in the interventions;
• •Chronic kidney disease with estimated glomerular filtration \< 30 mL/min per 1.73m²;
• •Liver failure, chronic viral hepatitis;
• •Grade III or IV heart failure
• •Active or progressive neurodegenerative disease;
• •Prior stroke that has caused sequelae;
• •Use of medications that affect glucose metabolism (e.g. corticosteroids or immunosuppressants) or cause weight loss;
• •Chronic treatment with oral or parenteral corticosteroids (\>7 days consecutive treatment) within 4 weeks prior to screening;
• •Treatment with weight-reducing agents (eg, orlistat, sibutramine, topiramate, bupropion, liraglutide, semaglutide) within the last 12 weeks before screening;
• •Treatment with thyroid hormone that was not maintained at a stable dose in last 12 weeks before screening;
• •History of active substance abuse (including alcohol) within the last year;
• •Thyroid Stimulating Hormone (TSH) outside the normal range;
• •Fasting triglycerides ≥ 600 mg/dL;
• •Tumor diagnosed and/or treated (except basal cell skin cancer, carcinoma in situ of the cervix, or prostate cancer in situ) within the last 5 years;
• •Severe psychiatric illness;
• •Predisposition or diagnosis of eating disorders;
• •Women who are pregnant, intend to become pregnant during the study period, or who are currently breastfeeding;
• •Hyperglycemia characterized by acute symptoms: polyuria, polydipsia and/or weight loss in the last 3 months;
• •Metabolic and acute complications of diabetes such as ketoacidosis or hyperosmolar coma;
• •Potentially unreliable patients and those deemed by the investigator to be unsuitable for the study;
• •Night workers who work after 10pm;
• •Being on a vegetarian, vegan or flexitarian diet at the time of recruitment;
• •Having undergone bariatric surgery;
• •Carriers of the human immunodeficiency virus (HIV);
• •Any other medical condition/disorder that the investigators consider that are likely to: interfere with the patient's ability to complete the entire study period or participate in study activities;
• •Participants who require any treatment that could affect the interpretation, reliability or safety of data during the study intervention.